Table 1 Study characteristics summary
From: The effectiveness of HPV vaccination on the incidence of oropharyngeal cancers in men: a review
Study | Study type | Characteristics | |
|---|---|---|---|
Number of participants | Outcome measure | ||
Chaturvedi et al. [23] | Cross sectional study | 2627 | Infections in vaccinated (0%) versus unvaccinated men (2.13%) |
Jamieson et al. [24] | Prospective cohort study | 910 | HPV positivity in saliva rose 34% to 44% at 1 year |
Katz et al. [25] | Cross section study | 3013 had a history of oropharyngeal cancer and 7732 were HPV vaccinated@@Of those with oropharyngeal cancer 1 had received the HPV vaccine and 3012 had not | Risk ratio increase of 23.8 (P = 0.0015) of developing oropharyngeal cancer in the male subgroup |
MacCosham et al. [26] | Randomised Controlled Trial | 167 couples so far | No results as yet |
Nielsen et al. [27] | Systematic Review | 48,777 | Relative Prevention Percentage (RPP) of 83.9% following vaccination, from the cross-sectional studies as well as an RPP of 82.4% from the included randomised controlled trial and 83% in the longitudinal cohort study29 |
Parker et al. [28] | Single arm intervention trial | 150 | 93.2% had oral anti HPV16 antibodies seven months post HPV vaccination |
Tsentemeidou et al. [13] | Systematic Review and meta-analysis | 13,285 | Those who had received HPV vaccination were had an 80% decreased risk of having oral HPV16 compared to unvaccinated individuals (P < 0.0001) |